CN110200971A - 多韦替尼在抗结核分枝杆菌药物中的应用 - Google Patents
多韦替尼在抗结核分枝杆菌药物中的应用 Download PDFInfo
- Publication number
- CN110200971A CN110200971A CN201910440659.1A CN201910440659A CN110200971A CN 110200971 A CN110200971 A CN 110200971A CN 201910440659 A CN201910440659 A CN 201910440659A CN 110200971 A CN110200971 A CN 110200971A
- Authority
- CN
- China
- Prior art keywords
- buddhist nun
- weis
- mycobacterium tuberculosis
- drug
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000187479 Mycobacterium tuberculosis Species 0.000 title claims abstract description 18
- 239000003814 drug Substances 0.000 title claims abstract description 17
- 229940079593 drug Drugs 0.000 title claims abstract description 17
- 201000008827 tuberculosis Diseases 0.000 claims abstract description 8
- 230000002365 anti-tubercular Effects 0.000 claims description 9
- 241000193830 Bacillus <bacterium> Species 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 6
- 238000011161 development Methods 0.000 abstract description 4
- 238000011160 research Methods 0.000 abstract description 3
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- 150000003384 small molecules Chemical class 0.000 abstract description 2
- 230000004614 tumor growth Effects 0.000 abstract description 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 abstract description 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 abstract description 2
- 230000033115 angiogenesis Effects 0.000 abstract 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 15
- 230000004083 survival effect Effects 0.000 description 9
- 210000002540 macrophage Anatomy 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 3
- 230000031700 light absorption Effects 0.000 description 3
- 201000009671 multidrug-resistant tuberculosis Diseases 0.000 description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108010019160 Pancreatin Proteins 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229940055695 pancreatin Drugs 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 description 1
- 108010041308 Endothelial Growth Factors Proteins 0.000 description 1
- 108091008794 FGF receptors Proteins 0.000 description 1
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 1
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 description 1
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N Lactic Acid Natural products CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- NHJSWORVNIOXIT-UHFFFAOYSA-N PD-166866 Chemical compound COC1=CC(OC)=CC(C=2C(=NC3=NC(N)=NC=C3C=2)NC(=O)NC(C)(C)C)=C1 NHJSWORVNIOXIT-UHFFFAOYSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940072185 drug for treatment of tuberculosis Drugs 0.000 description 1
- 208000036984 extensively drug-resistant tuberculosis Diseases 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000000814 tuberculostatic agent Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及多韦替尼在抗结核分枝杆菌药物中的应用。多韦替尼是一种口服活性小分子酪氨酸激酶抑制剂,对多种参与肿瘤生长和血管生成的RTK具有强大的抑制活性;而本发明研究发现其具有抗结核的作用,具有很好的开发价值;本发明涉及的多韦替尼在抗结核分枝杆菌药物中的应用以及多韦替尼具有明显的抗结核分枝杆菌的作用属于首次公开。
Description
技术领域
本发明涉及生物工程技术领域,特别涉及多韦替尼在抗结核分枝杆菌药物中的应用。
背景技术
2014年,WHO估算全球新发生48万MDR-TB病例,其中仅有约26%的病例得到检测和报告。MDR-TB队列的全球平均治疗成功率为50%,而严重耐多药结核(XDR-TB)的治疗成功率不到25%。因此,研发有效治疗结核病的新药/新方案,以提高治疗效果,缩短疗程,减少毒副作用,克服临床耐药是当前结核病防控的重大课题和研究热点。
多韦替尼是一种口服活性小分子酪氨酸激酶抑制剂,对多种参与肿瘤生长和血管生成的RTK具有强大的抑制活性。临床前数据显示,多韦替尼可抑制与不同癌症相关的多种激酶,包括急性髓性白血病(AML)和多发性骨髓瘤;与许多仅靶向血管内皮生长因子(VEGF)的激酶抑制剂不同,多韦替尼抑制成纤维细胞生长因子(FGF)途径中的受体,以及VEGF和血小板衍生生长因子(PDGF)。FGF受体酪氨酸激酶抑制对于癌细胞表达高水平表面FGF受体的一组骨髓瘤患者具有治疗意义。先期实验证明多韦替尼对FGFR1扩增的肿瘤细胞株,具有潜在抗肿瘤活性。
多韦替尼化学名为4-氨基-5-氟-3-[6-(4-甲基-1-哌嗪基)-1H-苯并咪唑-2-基]-2(1H)-喹啉酮2-羟基丙酸盐一水物,分子式为C24H27FN6O4,分子量为482.51,其结构式如下:
本研究发现此药具有抗结核的作用,具有很好的开发价值。
发明内容
本发明的目的是研发高效的抗结核新药,发现了多韦替尼的抗结核作用以及在抗结核分枝杆菌药物中的应用,安全性高,具有很好的开发价值。
本发明的技术方案主要为多韦替尼在抗结核分枝杆菌药物中的应用。
进一步地,结核分枝杆菌具体为结核分枝杆菌H37Rv。
本发明还提供了多韦替尼在制备抗结核药物中的应用。
在本发明的一个实施例方案中,提供了一种有效成分为多韦替尼的抗结核药物。这种抗结核药物能够应用于治疗结核病。
本发明的优点在于:
(1)本发明首次发现了多韦替尼具有明显的抗结核分枝杆菌的作用,作为潜在的靶向HDT的药物,已经被FDA批准,安全性高,具有很好的开发价值;
(2)本发明首次提出了多韦替尼在制备抗结核药物中的应用;
(3)本发明发现了多韦替尼在细胞中可以显著增强细胞杀伤结核菌。
附图说明
图1为本发明实施例1中不同浓度多韦替尼对细胞的存活率的影响;
图2为本发明实施例2中多韦替尼对细胞中结核分枝杆菌存活率的影响。
具体实施方式
下面结合附图和具体实施方式对本发明做进一步说明,以下实施例旨在说明本发明而不是对本发明的进一步限定。
本发明测定多韦替尼在细胞内抗结核分枝杆菌的活性,结果显示多韦替尼具有抗结核分枝杆菌的作用。
以下实施例中所用的技术手段为本领域技术人员所熟知的常规手段,所有原料均为通用材料。
实施例1
1.U937巨噬细胞(编号BNCC100967)的分化:将悬浮的U937巨噬细胞培养于含有10%FBS的RPMI-1640培养基中,并放置于温度为37℃,含有5%CO2的细胞培养箱中培养,加入终浓度为20ng/ml的PMA,培养过夜,将其分化成巨噬细胞,用PBS清洗两遍,利用胰酶消化、重悬后,加入96孔细胞培养板中,使每孔的细胞数为1x104个;
2.细胞存活率的测定:将上述U937巨噬细胞培养24h后,加入不同浓度的药物,使药物终浓度为100uM、10uM、1uM,每个浓度分别重复3次实验,利用DMSO作为平行对照实验,对照组中加入与药物体积相同的DMSO,分别重复3次实验,在48h后每孔加入10ulWST-1溶液,在温度为37℃的条件下继续培养4h,利用酶标仪测定OD450nm吸光值;
细胞存活率按照以下公式计算:
细胞存活率%=[A/A0]×100;其中,A0为DMSO对照的吸光值,A为不同浓度药物处理的吸光值。
图1表示不同浓度多韦替尼对细胞的存活率的影响;其中,“**”代表具有显著性差异,“ns”代表没有统计学差异。
实验结果显示,多韦替尼浓度为100uM、10uM、1uM,对应的细胞存活率分别为:52%、100%、100%;当药物浓度为10uM时,细胞存活率与对照组相比没有统计学差异。
实施例2:
1.U937巨噬细胞的分化:将悬浮的U937巨噬细胞培养于含有10%FBS的RPMI-1640培养基中,并于放置于温度为37℃,含有5%CO2的细胞培养箱中培养,加入终浓度为20ng/ml的PMA,培养过夜,将其分化成巨噬细胞,用PBS洗两遍,利用胰酶消化、重悬后,加入96孔细胞培养板中,使每孔的细胞数为1x104个;
2.细胞内杀菌活性测定:将上述U937巨噬细胞培养24h后,加入多韦替尼使其终浓度为10uM,每个浓度分别重复3次实验,利用DMSO作为平行对照实验,对照组中加入与药物体积相同的DMSO,分别重复3次实验,在4h后吸去培养基,用PBS洗两遍,加入新鲜培养基72h后加入裂解液,梯度稀释后涂布于7H10平板上,3周后计算菌落;
结果如附图2所示,利用10uM多韦替尼处理细胞,其对细胞中结核菌的存活率相对于对照组只有16.1%,而且在这个浓度下没有明显的细胞毒性,可用于开发高效、低毒的抗结核药物。
最后应说明的是:以上实施例仅用以说明本发明而并非限制本发明所描述的技术方案;本领域的普通技术人员应当理解,仍然可以对本发明进行修改或等同替换;而一切不脱离本发明的精神和范围的技术方案及其改进,其均应涵盖在本发明的权利要求限定的范围中。
Claims (7)
1.多韦替尼在抗结核分枝杆菌药物中的应用。
2.根据权利要求1所述的应用,其特征在于,所述抗结核分枝杆菌药物为体内抗结核分支杆菌的药物。
3.根据权利要求1所述的应用,其特征在于,所述结核分枝杆菌为结核分枝杆菌H37Rv。
4.多韦替尼在制备抗结核药物中的应用。
5.一种抗结核药物,其特征在于,所述药物有效成分为多韦替尼。
6.如权利要求5所述的一种抗结核药物的应用。
7.根据权利要求6所述的一种抗结核药物的应用,其特征在于,所述抗结核药物在治疗结核病中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910440659.1A CN110200971A (zh) | 2019-05-24 | 2019-05-24 | 多韦替尼在抗结核分枝杆菌药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910440659.1A CN110200971A (zh) | 2019-05-24 | 2019-05-24 | 多韦替尼在抗结核分枝杆菌药物中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110200971A true CN110200971A (zh) | 2019-09-06 |
Family
ID=67788498
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910440659.1A Pending CN110200971A (zh) | 2019-05-24 | 2019-05-24 | 多韦替尼在抗结核分枝杆菌药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110200971A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110664811A (zh) * | 2019-09-18 | 2020-01-10 | 深圳市第三人民医院 | 阿法替尼在抗结核分枝杆菌药物中的应用 |
-
2019
- 2019-05-24 CN CN201910440659.1A patent/CN110200971A/zh active Pending
Non-Patent Citations (1)
Title |
---|
KORBEE, C.J.: "Host-directed therapy for intracellular bacterial Infections", 《HTTP://HDL.HANDLE.NET/1887/69481》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110664811A (zh) * | 2019-09-18 | 2020-01-10 | 深圳市第三人民医院 | 阿法替尼在抗结核分枝杆菌药物中的应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Caino et al. | PI3K therapy reprograms mitochondrial trafficking to fuel tumor cell invasion | |
Roh et al. | p53-Reactivating small molecules induce apoptosis and enhance chemotherapeutic cytotoxicity in head and neck squamous cell carcinoma | |
Ogata et al. | A novel anti-tumor agent, polyoxomolybdate induces apoptotic cell death in AsPC-1 human pancreatic cancer cells | |
CN107072987A (zh) | 使用 chk1 和 atr 抑制剂的组合治疗癌症的方法 | |
JP2011513483A5 (zh) | ||
CN105001168A (zh) | 三烷氧基取代的苯并喹唑啉类酪氨酸激酶抑制剂及其用途 | |
JP2008525461A (ja) | Erkプロテインキナーゼの選択的阻害剤およびその使用 | |
Noronha et al. | Inhibitors of ABL and the ABL-T315I mutation | |
US20200246344A1 (en) | Mitoflavoscins: targeting flavin-containing enzymes eliminates cancer stem cells (cscs) by inhibiting mitochondrial respiration | |
CN110200971A (zh) | 多韦替尼在抗结核分枝杆菌药物中的应用 | |
Ghassemifar et al. | MDM2 antagonism by nutlin-3 induces death in human medulloblastoma cells | |
CN107296807B (zh) | Malt1靶向抑制物在制备malt1依赖性肿瘤治疗药物中的应用 | |
CN109152766A (zh) | 用于增殖性疾病的组合疗法 | |
Harbour | Eye cancer: unique insights into oncogenesis the Cogan lecture | |
Baguley | Tumor stem cell niches: a new functional framework for the action of anticancer drugs | |
Ranza et al. | In-vitro effects of the tyrosine kinase inhibitor imatinib on glioblastoma cell proliferation | |
WO2020000704A1 (zh) | AMPK抑制剂Compound C在治疗肿瘤药物中的应用 | |
Maluchenko et al. | Inhibiting the pro-tumor and transcription factor FACT: Mechanisms | |
CN108309959A (zh) | N或o或c-二芳基取代衍生物的合成及其药学应用 | |
Xie et al. | RhoA/ROCK signaling regulates TGF-β1-Induced fibrotic effects in human pterygium fibroblasts through MRTF-A | |
US20120022048A1 (en) | Anti-proliferative substituted pyrazolo[3,4-d]pyrimidines derivatives (SPP) to inhibit immune activation, virus replication and tumor growth | |
CN110354127A (zh) | 乳酸依沙吖啶在抗结核分枝杆菌药物中的应用 | |
KR101793127B1 (ko) | Ret 억제제 및 egfr 억제제의 조합물을 유효성분으로 포함하는 비소세포폐암 치료용 조성물 | |
Marhalim et al. | Synergistic effects of GSK3 and p38 MAPK inhibitors on growth of Plasmodium falciparum ex vivo. | |
Marczi et al. | Biological properties of 4-methyl-2, 7-diamino-5, 10-diphenyl-4, 9-diazapyrenium hydrogensulfate (ADAP) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |